Research output per year
Research output per year
Search results
-
2025
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms: MYELODYSPLASTIC NEOPLASM
Bouligny, I. M., Montalban-Bravo, G., Sasaki, K., Daver, N., Jabbour, E., Alvarado, Y., DiNardo, C. D., Ravandi, F., Borthakur, G., Pemmaraju, N., Kadia, T., Masarova, L., Takahashi, K., Andreeff, M., Bazinet, A., Yang, H., Kanagal, R., Pierce, S., Meyer, M. & Huang, X. & 1 others, , Feb 2025, In: Leukemia. 39, 2, p. 524-528 5 p., 103208.Research output: Contribution to journal › Letter › peer-review
1 Scopus citations -
2023
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia
Bouligny, I. M., Murray, G., Ho, T., Doyel, M., Patel, T., Boron, J., Tran, V., Gor, J., Hang, Y., Alnimer, Y., Zacholski, K., Venn, C., Wages, N. A., Grant, S. & Maher, K. R., Nov 2023, In: Leukemia Research. 134, 107370.Research output: Contribution to journal › Letter › peer-review